For Cogent Biosciences Inc. (COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, 2026 is shaping up to be a pivotal year as its lead drug candidate Bezuclastinib approaches multiple regulatory and clinical milestones.
Bezclastinib is a potent type-1 tyrosine kinase inhibitor that blocks mutant KIT D816V activity while sparing other kinases, thereby minimising the potential for off-target side effects. KIT mutations serve as driver mutations in up to 80% of gastrointestinal stromal tumors (GIST) and in over 90% of systemic mastocytosis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com